Work

Abstract LB-200: Dose and schedule determination of the Chk1/2 inhibitor LY2606368 in patients with solid tumors.

Year: 2013

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2013-lb-200

Authors: Johanna C. Bendell, Filip Janku, Jeffrey Infante, Suzanne Jones, Howard Burris, Lisa Golden, Scott M. Hynes, Ji Lin, Aimee K. Bence, Susan Tse, Razelle Kurzrock, David Hong

Institutions: Sarah Cannon, The University of Texas MD Anderson Cancer Center, Eli Lilly (United States), University of California San Diego, Moores Cancer Center

Language: English

Topic: Cancer therapeutics and mechanisms

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2093207394

Cites:

Cited by: 1

Related to: 10